[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","commit":"f7782c9f5f","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on a further thirty companies","file":"src/data/spikes/cholangiocarcinoma.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.incyte.com\" }]"}]},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/cholangiocarcinoma.ts","type":"changed","fields":[{"field":"tldr","before":"\"Maker of pemigatinib, the first targeted drug approved for bile duct cancer (2020), and of the JAK inhibitor ruxolitinib.\"","after":"\"Incyte makes pemigatinib, the first targeted drug approved for bile duct cancer (2020), and the JAK inhibitor ruxolitinib.\""}]},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","commit":"2997dc2520","date":"2026-09-08","author":"Jude Gomila","message":"Deep cancer spikes: DLBCL, multiple myeloma, Hodgkin lymphoma, sarcoma, neuroblastoma (135 new entities with structured outcomes, dosing, to","file":"src/data/spikes/dlbcl.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"cancers"}]},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","commit":"06899fbdf4","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: hepatocellular carcinoma, biliary tract cancer, neuroendocrine tumours (deep, with structured outcomes, dosing, toxicity, regulatory","file":"src/data/spikes/cholangiocarcinoma.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"cancers"}]}]